LKFT — Lakefront Biotherapeutics NV Cashflow Statement
0.000.00%
Last trade - 00:00- €1.57bn
- -€1.41bn
- €1.11bn
Annual cashflow statement for Lakefront Biotherapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -103 | -218 | 212 | 74.1 | 321 |
| Depreciation | |||||
| Non-Cash Items | 5.46 | 15.2 | -26.8 | -220 | 237 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -441 | -363 | -635 | -220 | -872 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -504 | -501 | -406 | -320 | -257 |
| Capital Expenditures | -57.9 | -36.9 | -19.3 | -82.1 | -13.9 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 599 | -1,209 | 90.5 | 303 | 303 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 541 | -1,246 | 71.2 | 221 | 289 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3.88 | -1.49 | -5 | -4.92 | -3.27 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 90.3 | -1,725 | -341 | -103 | 23.6 |